Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 6
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Aspinall, Esther Jane Doyle, Joseph Samuel Corson, Stephen Hellard, Margaret Elena Hunt, David Goldberg, David Nguyen, Tim Falck-Ytter, Yngve Morgan, Rebecca Lynn Smith, Bryce Stoove, Mark Wiktor, Stefan Zbyszko and Hutchinson, Sharon 2015. Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. European Journal of Epidemiology, Vol. 30, Issue. 2, p. 115.

    Sharma, Suraj Carballo, Manuel Feld, Jordan J. and Janssen, Harry L.A. 2015. Immigration and viral hepatitis. Journal of Hepatology, Vol. 63, Issue. 2, p. 515.

    Tissot, Jean-Daniel Danic, Bruno and Schneider, Thierry 2015. Transfusion sanguine : en toute sécurité d’approvisionnement. La Presse Médicale, Vol. 44, Issue. 2, p. 178.

    Croes, Esther and van der Veen, Clary 2013. Aandacht gevraagd voor hepatitis C in de verslavingszorg. Verslaving, Vol. 9, Issue. 2, p. 34.

    Hahné, Susan JM Veldhuijzen, Irene K Wiessing, Lucas Lim, Tek-Ang Salminen, Mika and Laar, Marita van de 2013. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infectious Diseases, Vol. 13, Issue. 1,

    Helsper, Charles 2013. Hepatitis C – opsporing verzocht. Huisarts en wetenschap, Vol. 56, Issue. 1, p. 22.


Cost-effectiveness of targeted screening for hepatitis C in The Netherlands

  • C. W. HELSPER (a1), B. A. BORKENT-RAVEN (a1), N. J. DE WIT (a1), G. A. VAN ESSEN (a1), M. J. M. BONTEN (a1) (a2), A. I. M. HOEPELMAN (a2), M. P. JANSSEN (a1) and G. A. DE WIT (a1) (a3)
  • DOI:
  • Published online: 16 February 2011

On account of the serious complications of hepatitis C virus (HCV) infection and the improved treatment possibilities, the need to improve HCV awareness and case-finding is increasingly recognized. To optimize a future national campaign with this objective, three pilot campaigns were executed in three regions in The Netherlands. One campaign was aimed at the general population, a second (similar) campaign was extended with a support programme for primary care and a third campaign was specifically aimed at hard-drug users. Data from the pilot campaigns were used to build a mathematical model to estimate the incremental cost-effectiveness ratio of the different campaigns. The campaign aimed at the general public without support for primary care did not improve case-finding and was therefore not cost-effective. The similar campaign accompanied by additional support for primary care and the campaign aimed at hard-drug users emerged as cost-effective interventions for identification of HCV carriers.

Corresponding author
*Author for correspondence: C. W. Helsper, M.D., Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands, PO Box 85500, 3508 GA Utrecht, The Netherlands. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.CW Shepard , L Finelli , MJ Alter . Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005; 5: 558567.

2.World Health Organisation.Hepatitis C: global prevalence. Weekly Epidemiological Record 1997; 72: 341344.

3.GM Lauer , BD Walker . Hepatitis C virus infection. New England Journal of Medicine 2001; 345: 4152.

4.MP Manns , The way forward in HCV treatment-finding the right path. Nature Reviews Drug Discovery 2007; 6: 991–1000.

5.J Thompson-Coon , Case finding for hepatitis C in primary care: a cost utility analysis. Family Practice 2006; 23: 393406.

6.GR Foster , Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. British Medical Journal 1997; 315: 453458.

8.MEE Kretzschmar .The prevalence of hepatitis C in the Netherlands [in Dutch]. Bilthoven, the Netherlands, National Institute of Public Health and the Environment, 2004; publication number VWS-IGZ 2004/02 – Project V/210041.

9.A Kok , Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2007; 151: 23672371.

11.MJ de Vries , B te Rijdt , CM van Nieuwkerk . Transmission of hepatitis C genotypes in the Netherlands amongst recently genotyped patients. Netherlands Journal of Medicine 2008; 66: 4041.

12.C Frank , The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887891.

13.MI Meltzer . Introduction to health economics for physicians. Lancet 2001; 358: 993998.

14.CW Helsper , A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Practice 2010; 27: 328332.

17.U Siebert , Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425432.

19.B Smyth , J Fan , YI Hser . Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. Journal of Addictive Diseases 2006; 25: 3747.

20.Organisation for Economic Cooperation and Development (OECD). Health Data 2007 (CD-ROM), 2007.

24.E Op de Coul , A Bosman , M van de Laar . Surveillance of hepatitis C in the Netherlands, 1992–2002 [in Dutch]. Infectieziekten Bulletin 2003; 9: 323328.

25.DJ de Jong , Referral of hepatitis C virus seropositive patients in primary care in the Netherlands. Netherlands Journal of Medicine 2008; 66: 4243.

27.Statistics Netherlands (CBS). CBS table: Population per region subdivided to country and gender Database ( Accessed 1 January 2006.

29.E Castelnuovo , The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment 2006; 10: xiii–iv, ixxii, 193.

30.K Stein , Screening for hepatitis C in injecting drug users: a cost utility analysis. Journal of Public Health (Oxford) 2004; 26: 6171.

31.G Sroczynski , Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. European Journal of Public Health 2009; 19: 245253.

33.JMG Wilson , G Jungner . Principles and practice of mass screening for disease. Boletín de la Oficina Sanitaria Panamericana 1968; 65: 281393.

34.A Andermann , Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization 2008; 86: 317319.

35.IK Veldhuijzen , Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138: 522530.

36.AD Paltiel , Expanded screening for HIV in the United States – an analysis of cost-effectiveness. New England Journal of Medicine 2005; 352: 586595.

37.SA Bozzette . Routine screening for HIV infection-timely and cost-effective. New England Journal of Medicine 2005; 352: 620621.

38.V Soriano , MG Peters , S Zeuzem . New therapies for hepatitis C virus infection. Clinical Infectious Diseases 2009; 48: 313320.

39.S Zeuzem . Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5: 610622.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary Materials

Helsper Supplementary Material
Helsper Supplementary Tables

 Unknown (134 KB)
134 KB